The slide uses a 'villain critique' approach to frame the company's drug candidate as a failure, drawing parallels to a previous market failure (Aprea).
Slide schematic 9/9
list 7/7 source-note 1/1 title 1/1
Components 9
bullet bullet bullet bullet bullet bullet bullet source-note headline
Tools 0
∅
No tools

No canon tool match is anchored to this slide.

Metrics 0
∅
No metrics

No metric insight is anchored to this slide.

Frameworks 1